Navigation Links
Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
Date:7/8/2008

PALO ALTO, Calif., July 8 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK), today announced the publication of research in Bioorganic & Medicinal Chemistry Letters describing a novel class of small molecule compounds that could potentially lead to a new treatment for diabetes. These unique compounds are the result of an extensive medicinal chemistry effort at Telik to optimize the original lead structure identified through the application of Telik's TRAP(R) technology.

The compounds developed activate the insulin receptor and may have the potential to be an orally administered treatment for diabetes. Such small molecules have been actively sought after since the discovery of insulin in the 1920s by Banting and Best, and could represent a completely different approach to the treatment of Type 1 and Type 2 diabetes. Telik's publication, Robinson, L. et al., "5-Substituted isophthalamides as insulin receptor sensitizers," Bioorg. Med. Chem. Lett., 18: 3492 (2008), describes a series of compounds that are capable of activating the insulin receptor and were also shown to increase glucose transport into adipocytes.

"Telik's drug development focus does not include diabetes and other metabolic diseases," said Marc Steuer, Senior Vice President, Business Development. "It is our intention, therefore, to seek a licensee with the requisite development skills and expertise in this therapeutic area."

About Telik

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com.

This press release contains "forward-looking" statements, including statements regarding the potential capabilities and qualities of the small molecules described above. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended March 31, 2008. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
2. Telik Announces First Quarter 2008 Financial Results
3. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
4. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
5. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
6. Telik Announces Year-End Financial Release, Conference Call and Webcast
7. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
8. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
9. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
10. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
11. Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... 18, 2017 , ... Optofluidics today announced that it's changing ... company changed focus to making analytical tools for biopharmaceutical quality control. “We are ... CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson have steered ...
(Date:4/19/2017)... ... April 19, 2017 , ... WHO: Peggy Lillis Foundation, ... education and advocacy. Founded in 2010 in memory of a single-parent mom and ... has become the most-consulted source for patient-focused information on C. diff infections in ...
(Date:4/19/2017)... , April 19, 2017  As a ... and Heroin Summit ,  Proove® Biosciences, Inc. ... genetics, environmental, and lifestyle factors to accurately predict ... University of Southern California (USC), the Interventional Pain ... Proove publish results showing that Proove Opioid Risk® ...
(Date:4/19/2017)... 19, 2017   Thermo Fisher Scientific Inc ... Procalcitonin MOnitoring SEpsis (MOSES) Study have been published ... Critical Care Medicine . Researchers from the study, ... Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis ... PCT (procalcitonin) assay to assess risk for 28 ...
Breaking Biology Technology:
(Date:3/9/2017)... Australia , March 9, 2017 4Dx ... prestigious World Lung Imaging Workshop at the University of ... was invited to deliver the latest data to world ... recognised event brings together leaders at the forefront of ... in lung imaging. "The quality of ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today ... to uncover insights to support its reporting, help direct future ... UK,s leading youth charity will be using Brandwatch Analytics social listening ... better understanding of the topics and issues that are a priority ... ...
(Date:3/6/2017)... 6, 2017 Mintigo , the ... announced Predictive Sales Coach TM , its new ... intelligence into Salesforce. This unique AI application will ... organizations with deep knowledge of their customers and ... engagement. Predictive Sales Coach extends Mintigo,s existing customer ...
Breaking Biology News(10 mins):